Novo’s $165m REPAIR fund seeks to support projects from LO to Phase 1

Dear All:

Just announced today (press releasewebsite), Novo Holdings has created a $165m impact fund that seeks to support novel therapies from Lead Optimization (LO) through Phase 1. The fund specifically targets “first-in-class therapies, covering small molecules, biologics, and new modalities.” Similar to the focus of CARB-X, REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) will focus on priority pathogens from the CDC and WHO priority lists. 

The origin of the idea for this project appears to be from social impact goals of the Novo Nordisk Foundation: “The vision of the Foundation is to contribute significantly to research and development that improves the health and welfare of people. The Foundation donates about $300-600 million per year primarily for medical research.”

A first round of investments dedicated to European companies will start in April 2018 (non-confidential presentations can be sent until 15 May 2018) and is expected to lead to investments by the end of 2018. A second round of investments focusing on United States companies will start in the fall 2018.

All told, the fund expects to invest USD 20-40 million per year over 3–5 years in about 20 projects in Europe and the United States. The overall goal is at least one new therapy reaching the market.

It’s exciting to see this additional source of push funding! Although funds from REPAIR are presumably dilutive in nature (rather than the non-dilutive financing of CARB-X), the availability of funds from a group who understand the challenge and opportunity of antimicrobial resistance will be a powerful new force for progress. Thank you, Team Novo!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1 Dear All (and with thanks to Kevin Outterson for being lead author on this newsletter), (wonkish alert on this one … refresh your coffee and dig in!) The Center for Global Development have released a blog post and a paper estimating the potential impact of the PASTEUR Act.

Five FDA RFPs! Antifungal animal models, MIC breakpoints, and more!

Dear All, I just today learned that FDA have posted their FY 2023 funding opportunities. All the details are on this webpage and I’m just going to reproduce the text below my signature for your reference. I’ll also add a few details in italics. Lots of good opportunities here! –jr John H. Rex, MD |

WAAW! Must-Read Article, A Quiz, A Video, A Call to Action

Notes: Newsflash … BARDA have opened their long-running BAA-18-100-SOL-00003 to include support for antifungal agents. Search for “antifungal” in the posted .pdf to find the text. The first deadline for proposals is 15 Dec 2022 and further deadlines will doubtless follow: as shown on page 9, this BAA has offered 4 deadlines/year since 2018!  Dear All, In

Fireside Chat with AMR Action Fund CIO Martin Heidecker

Dear All, Ahead of World Antimicrobial Awareness Week, I sat down with AMR Action Fund Chief Investment Officer Martin Heidecker for a Fireside Chat. It was a fabulous conversation that covered everything from how the Fund’s investment process works to what it’s looking for in portfolio companies to broader investment trends in the AMR space.  As

Scroll to Top